Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2011-05-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Krill Oil
Krill oil
Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
Fish Oil
Fish Oil
Fish oil: Total omega-3 fatty acids: 560-660 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Krill oil
Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
Fish Oil
Fish oil: Total omega-3 fatty acids: 560-660 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* rheumatoid arthritis
* chronic illness
* cardiovascular problems
* dyslipidemia
* liver and kidney disease
* diabetes
* endocrine or metabolic disease
* inflammatory bowel disease
* pancreatitis
* gallbladder or biliary disease
* neurological/psychological disease
* bleeding disorders
* experienced platelet abnormalities
* gastrointestinal disorders that could interfere with fat absorption
* hypertension
* history of cancer
* an intention to lose weight
* use of anticoagulant
* serum triglycerides (TG) \>200 mg/dL, and/or total cholesterol (TC) \>240 mg/dL, and/or LDL-cholesterol (LDL-C) \>160 mg/dL
* hypertension or lipid lowering medications
* consumption of more than one alcoholic drinks/day
* Consumption of more than one fish or seafood serving
* one month prior to the start of the study
* omega-6 fatty acids in the past 6 months
* planned to consume seafood products or fish or to use any omega-3 or omega-6 fatty acids nutritional supplements at anytime in the duration of the study
* planned to to become pregnant during the study period
* BMI\>28
* allergies to fish seafood or corn
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Enzymotec
INDUSTRY
University of Manitoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Peter Jones
Director of RCFFN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ramprasath VR, Eyal I, Zchut S, Shafat I, Jones PJ. Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids Health Dis. 2015 Nov 4;14:142. doi: 10.1186/s12944-015-0142-y.
Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. 2013 Dec 5;12:178. doi: 10.1186/1476-511X-12-178.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2011:014
Identifier Type: -
Identifier Source: org_study_id